A Phase 1 interventional study of Flortaucipir F18 and Brain PET scan in Cognitive Decline, sponsored by Avid Radiopharmaceuticals. Terminated at 1 site in United States. Per ClinicalTrials.gov, last updated 2020-09-25.
Sponsored by Avid Radiopharmaceuticals (part of Eli Lilly and Company) · Phase 1, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Cognitive Dysfunction by Eli Lilly and Company — 5 open to participants now, 8 under way, 2 of them phase 3. Cognitive Dysfunction · Eli Lilly and Company.
Among the 24 studies in Cognitive Dysfunction by Eli Lilly and Company, this one is the 22nd largest by enrollment of the 22 interventional ones that give a count, is the only one that started in 2017, is one of 7 in phase 1, and was the 11th registered.
3,878 studies on the registry are indexed under Cognitive Dysfunction; 1,120 are open to participants now.
Browse Cognitive Dysfunction studies →5 of the 24 studies in Cognitive Dysfunction by Eli Lilly and Company are open now, in 9 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United Arab Emirates
Ages 55+
Eli Lilly and Company · Sites in United States, Australia, New Zealand and 1 more country
Ages 50–85
Eli Lilly and Company · Sites in United States, Japan, Korea, Republic of and 1 more country
Ages 55–85
Eli Lilly and Company · Sites in United States
Ages 50+
Eli Lilly and Company · Sites in United States, Japan, United Kingdom
Ages 50–85
By country, each count listing its studies:
Of the 753 Cognitive Dysfunction studies recruiting now, 363 (48%) set no upper age limit and 143 (19%) stop at 75 or younger; 46 take children under 18; 261 take healthy volunteers.
This study: all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 8 · Phase 3 6
First in 2008; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 64 across 2,799 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 152 across the 22 interventional studies, 800 across the 2 observational. Of the 16 that completed or were terminated, 15 (94%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Avid Radiopharmaceuticals, one of the names counted as Eli Lilly and Company. Under that name alone:
Avid Radiopharmaceuticals is the lead sponsor of 54 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 10 (91%) have results posted.
3 of the studies in Cognitive Dysfunction by Eli Lilly and Company that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07598370Eli Lilly and CompanyA Study of LY3439539 in Participants With Alzheimer's Disease | 2027-08 |
| NCT07254234Eli Lilly and CompanyA Study of Retinal Imaging to Detect Abnormal Protein Deposits Associated With Alzheimer's Disease | 2027-09 |
| NCT07140744Eli Lilly and CompanyA Study Evaluating the Impact of P-tau217 Blood Biomarker Testing on Early Evaluation and Management of Patients Presenting With Cognitive Complaint | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 24 studies in Cognitive Dysfunction by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is designed to assess the imaging characteristics of Flortaucipir (18F-AV-1451) in subjects who participated in the Biomarkers of Cognitive Decline Among Normal Individuals (BIOCARD) study at Johns Hopkins University.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically normal amyloid positive subjects from BIOCARD study receiving a flortaucipir PET scan
Drug: Flortaucipir F18 · Procedure: Brain PET scan
Clinically normal amyloid negative subjects from BIOCARD study receiving a flortaucipir PET scan
Drug: Flortaucipir F18 · Procedure: Brain PET scan
370 megabecquerel (MBq)(10 millicurie \[mCi\]) single dose
Also known as: 18F-AV-1451, [F-18]T807, LY3191748, Tauvid
positron emission tomography (PET) scan of the brain
Qualitative Evaluation of Scan Results
Subject scans were visually evaluated by an expert reader into three groups. Advanced Alzheimer's disease (AD) scan pattern = In either hemisphere, increased neocortical activity in the parietal/precuneus region(s), or frontal region(s) with increased uptake in the posterolateral temporal (PLT), parietal, or occipital region(s). Moderate AD scan pattern = In either hemisphere, increased neocortical activity limited to the PLT or occipital region(s). Not AD scan pattern = No increased neocortical activity, or increased neocortical activity isolated to the mesial temporal, anterolateral temporal, and/or frontal regions.
Time frame: Baseline scan
Quantitative Evaluation of Scan Results
Standard Uptake Value Ratio (SUVr) by amyloid status using a weighted cortical average. For SUVr, a value of 1 or lower signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.
Time frame: 75 minutes post dose administration
Enrollment took place between Mar 2017 and Aug 2018 from the Biomarkers of Cognitive Decline Among Normal Individuals (BIOCARD) study
| Milestone | Amyloid Positive | Amyloid Negative |
|---|---|---|
| Started | 18 | 5 |
| Completed | 18 | 5 |
| Not completed | 0 | 0 |
Subject scans were visually evaluated by an expert reader into three groups. Advanced Alzheimer's disease (AD) scan pattern = In either hemisphere, increased neocortical activity in the parietal/precuneus region(s), or frontal region(s) with increased uptake in the posterolateral temporal (PLT), parietal, or occipital region(s). Moderate AD scan pattern = In either hemisphere, increased neocortical activity limited to the PLT or occipital region(s). Not AD scan pattern = No increased neocortical activity, or increased neocortical activity isolated to the mesial temporal, anterolateral temporal, and/or frontal regions.
| Participants | Amyloid Positive | Amyloid Negative |
|---|---|---|
| Advanced AD Scan Pattern (τAD++) | 11 | 0 |
| Moderate AD Scan Pattern (τAD+) | 0 | 0 |
| Not AD Scan Pattern (τAD-) | 6 | 5 |
Standard Uptake Value Ratio (SUVr) by amyloid status using a weighted cortical average. For SUVr, a value of 1 or lower signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.
| standardized uptake value ratio (SUVr) | Amyloid Positive | Amyloid Negative | Total |
|---|---|---|---|
| Quantitative Evaluation of Scan Results | 1.0414 ± 0.04165 | 1.0219 ± 0.02057 | 1.0371 ± 0.03854 |
Collected over AEs were collected at scan visits and for 48 hours after flortaucipir administration.. Non-serious events are listed at a 0.5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Amyloid Positive | 0/18 (0%) | 0/18 (0%) | 2/18 (11.1%) |
| Amyloid Negative | 0/5 (0%) | 0/5 (0%) | 0/5 (0%) |
| Event | Amyloid Positive | Amyloid Negative |
|---|---|---|
| Abdominal pain upperGastrointestinal disorders | 1/18 | 0/5 |
| DiarrhoeaGastrointestinal disorders | 1/18 | 0/5 |
| HeadacheNervous system disorders | 1/18 | 0/5 |
| Age, Continuous(years) | Amyloid Positive | Amyloid Negative | Total |
|---|---|---|---|
| Mean | 72.1 ± 5.69 | 66.8 ± 7.53 | 70.9 ± 6.35 |
| Sex: Female, Male(Participants) | Amyloid Positive | Amyloid Negative | Total |
|---|---|---|---|
| Female | 10 | 4 | 14 |
| Male | 8 | 1 | 9 |
| Ethnicity (NIH/OMB)(Participants) | Amyloid Positive | Amyloid Negative | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 2 |
| Not Hispanic or Latino | 17 | 4 | 21 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Amyloid Positive | Amyloid Negative | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 18 | 5 | 23 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Amyloid Positive | Amyloid Negative | Total |
|---|---|---|---|
| United States | 18 | 5 | 23 |
| MMSE(units on a scale) | Amyloid Positive | Amyloid Negative | Total |
|---|---|---|---|
| Mean | 29.3 ± 1.02 | 29.2 ± 1.30 | 29.3 ± 1.05 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2017 to primary completion in Aug 2018, 16 months.
Results were first posted in Aug 2020, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Flortaucipir